Table 2.

Serological profile of participants and rituximab exposure.

Characteristics	N = 25	p-Value
Anti-HBs (mIU/mL)
Before rituximab	162 (10.4–1000)	0.04
After rituximab	83 (3–1000)
Anti-HBs before rituximab (n)
Anti-HBs ≥ 100 mIU/mL (%)	14 (56.0%)
Anti-HBs < 100 mIU/mL (%)	11 (44.0%)
Anti-HBs after rituximab (n)
Anti-HBs ≥ 100 mIU/mL (%)	12 (48.0%)
Anti-HBs < 100 mIU/mL (%)	13 (52.0%)
Time (months) between the first and second anti-HBs measurements.	5.5 (±2.5)
Amount of rituximab doses between first and second anti-HBs measurements.	4.4 (±1.9)